UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close
Already an Engineering360 user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your Engineering360 Experience

close
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

CLSI EP14

Evaluation of Matrix Effects; Approved Guideline

inactive
Buy Now
Organization: CLSI
Publication Date: 1 January 2005
Status: inactive
Page Count: 48
scope:

This guideline is intended for diagnostic test manufacturers, external quality control and proficiency testing providers, and regulatory agencies. Although clinical laboratory use will probably be limited because of the complexity of the calculations, the observations and conclusions should be useful to all professionals. The guideline provides protocols that evaluate matrix effects in processed samples that are used as standards, calibrators, controls, and EQA/PT materials.

EP14 will assist in the education of clinical laboratorians, regulators, diagnostic manufacturers, and the public about the impact of matrix effects on the assessment of the quality of laboratory performance. For example, readers are warned that matrix effects, caused by the interaction of processed material and the measurement procedure, may suggest that erroneous results are being generated when in fact the results are acceptable. Conversely, "acceptable" control results may also give a false sense of confidence that procedures are performing adequately. Terms and concepts used to report these and related issues are defined within this document.

This guideline can be used by laboratorians performing quantitative tests for a wide variety of analytes across various disciplines. The testing protocols attempt to accommodate situations where reference methods do not exist.

The protocols help laboratorians distinguish between effects caused by measurement procedure malfunctions and those caused by use of processed samples. However, the protocols do not describe approaches that specifically establish the exact mechanism of the matrix effect(s).

By following the protocols, manufacturers and EQA/PT providers should be able to provide some documentation to government or accrediting agencies on matrix effects to help avoid false conclusions about the adequacy of patient testing.

Document History

August 1, 2014
Evaluation of Communtability of Processed Samples; Approved Guideline
This guideline provides protocols that can evaluate commutability in any nonpatient processed samples when tested using quantitative measurement procedures. Such processed samples may be used for...
CLSI EP14
January 1, 2005
Evaluation of Matrix Effects; Approved Guideline
This guideline is intended for diagnostic test manufacturers, external quality control and proficiency testing providers, and regulatory agencies. Although clinical laboratory use will probably be...

References

Advertisement